Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment ...
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmac ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Asian News International on MSN3d
Shilpa Medicare Secures SEC-CDSCO Nod For Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch For NASHNAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic ...
A group of state lawmakers and a Macomb County official want stricter limits than the state proposes for Oakland County's ...
A group of around half a dozen pharma companies are trying to develop treatment for NASH, for which there is no approved treatment. The market for NASH drugs is expected to exceed $1 billion soon ...
Fintel reports that on March 14, 2025, Goldman Sachs initiated coverage of 89bio (NasdaqGM:ETNB) with a Neutral ...
Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback